Jothydev Kesavadev

Honored to speak at ATTD 2026, Barcelona,Spain,(Advanced Technologies & Treatments for Diabetes), one of the world’s largest and most influential technology conferences in diabetes. My presentation focused on an exciting and rapidly evolving area: “Experience Integrating AI in our EMR: DTMS-AI.” Over the past 3 decades, our clinical ecosystem has accumulated a rich longitudinal diabetes data bank through the Diabetes Tele Management System (DTMS). By securely integrating Artificial Intelligence within our EMR framework, we are now entering a new phase of diabetes care where data does far more than simply record history. AI integration enables: • Deep pattern recognition across years of patient data • Predictive analytics for early identification of clinical risks • Decision-support insights for clinicians at the point of care • Personalized treatment pathways based on real-world longitudinal data Importantly, the focus is on secure, ethical, and clinically meaningful deployment of AI, ensuring that technology augments physician intelligence rather than replacing it. During the session, I also demonstrated DTMS-AI in action, showcasing how AI can interact with decades of structured clinical data to generate clinically useful insights that may help transform the future of diabetes management. Grateful to distinguished colleagues Drs.Moshe Philip, Tadej Battelino, and Banshi Saboo for the opportunity to present in the D-Tech session at ATTD. @banshisaboo @dramitaol @drrakeshparikh @ManojCh00190740 Exciting times ahead as AI, digital therapeutics, and clinical medicine converge to redefine diabetes care. (Due to the ongoing global situation and travel constraints, I had to deliver my lecture virtually) #ATTD2026 #DiabetesTechnology #ArtificialIntelligence #DigitalHealth #PrecisionMedicine #DiabetesCare #ClinicalInnovation #DTMS #HealthcareAI #FutureOfMedicine

🚨Registrations are now OPEN for the 14th Annual Global Diabetes Convention-JPEF 2026, one of the oldest and respected diabetes conventions in India. For over 13 years, the Jothydev’s Professional Education Forum (JPEF) has been a platform dedicated to advancing diabetes knowledge, clinical excellence, and collaborative learning among healthcare professionals. We are delighted to continue this legacy with the 14th edition of our Global Diabetes Convention. 📅 July 10, 11 & 12, 2026 📍 Uday Samudra, Kovalam, Trivandrum Theme 2026: Helping You Choose the Best in Diabetes Care This three-day international convention will bring together leading experts, clinicians, and researchers to discuss evidence-based approaches, emerging therapies, technologies, and practical strategies for optimal diabetes management. 🔗 Registrations are now open: Link in the comment box We warmly invite colleagues and healthcare professionals from across the world to join us for three days of meaningful scientific exchange and learning. #JPEF2026 #GlobalDiabetesConvention #DiabetesCare #MedicalEducation #Diabetology #jothydevsprofessionaleducationforum

@ShashiTharoor Thanks @ShashiTharoor for sharing this remarkable story with the world. Kudos to John Mary, the celebrated journalist, for bringing it to light so powerfully.

A tale of indomitable spirit from Naruvamoodu, Thiruvananthapuram! It brings me profound happiness and special affection to share this conversation with Sreeja J.S., who just secured an AIR 57 in her very first UPSC attempt, opting for the Indian Foreign Service. As the daughter of a daily wage earner, her triumph against financial adversity is deeply inspiring. A double delight to see her beautifully interviewed by my good friend, veteran journalist John Mary. Do watch! youtu.be/13LKhsm0qe8?si…

📌 “Obesity is more than a lifestyle condition;for many patients, it’s a chronic disease that requires compassion, clinical care, and long-term support.” I’m grateful to Rinku Ghosh, Health Section Lead at The Indian Express, for her thoughtful coverage of obesity as a chronic disease in India. Read the full story in Indian Express at the following link in the comment box. Her article shines a critical spotlight on the lived experiences of people struggling with weight-related health burdens and moves the conversation beyond stigma and oversimplified advice. In the story, a young man’s journey from 150 kg with diabetes and hypertension to seeking care highlights what we see day in and day out in clinical practice: obesity profoundly impacts physical, mental and social wellbeing. As a clinician at Jothydev’s Diabetes Research Centre, I strongly believe obesity should be recognised as a chronic disease because: • It involves complex biological pathways and metabolic dysfunction. • It increases the risk of diabetes, cardiovascular disease, cancer, and many other complications. • It requires ongoing medical support, structured care plans, and emotional support-not just “eat less, move more.” Reframing obesity as a chronic disease honours the complexity of each person’s journey, reduces blame, and opens doors to better, more supportive care. Thanks again to The Indian Express for bringing this important narrative to a broader audience. 🙏 @unnishanker @IndianExpress #PatientCenteredCare #ObesityCare #ChronicDisease #MetabolicHealth #Diabetes #Healthcare #PublicHealth #CompassionInMedicine

I am pleased to share that our white paper on obesity in India has been featured in the The Times of India, in a report by Preetu Nair. As the second author of the paper published in the World Obesity Federation journal Clinical Obesity, I strongly reiterate a critical message: Obesity must be recognised as a chronic, complex disease, not merely a lifestyle condition. Despite the World Health Organization classifying obesity as a disease decades ago, India continues to treat it largely as a lifestyle issue. This perception fuels stigma, delays intervention, and worsens long-term health outcomes . Key concerns highlighted: • Obesity is linked to over 270 diseases • India had the third-largest number of adults with obesity globally in 2022 • 12.5 million children and adolescents in India are living with obesity • Kerala shows particularly high prevalence, with alarming abdominal obesity rates Our Obesity Advocacy Group Forum has recommended four transformative actions: 1️⃣ Official recognition of obesity as a complex chronic disease 2️⃣ Shift from reactive disease management to proactive health promotion 3️⃣ Strengthening healthcare systems for structured obesity care 4️⃣ Expanding societal and institutional support for people living with obesity Kerala, in particular, requires urgent primary prevention strategies, structured school-based physical activity, muscle strengthening programs, dietary literacy, and early screening for central adiposity . India stands at a critical juncture. Without policy reform, the medical, social, and economic burden will escalate dramatically. Grateful to the media for amplifying this important public health conversation. Heartiest congratulations and thanks to Dr Sanjay Kalra for taking the lead. @novonordisk #Obesity #PublicHealth #PolicyChange #NonCommunicableDiseases #KeralaHealth #HealthEquity #ClinicalObesity #PreventiveHealthcare

I am pleased to share a recent publication on Obesity burden in India in “International Journal Clinical Obesity” the official journal of the world obesity federation. Me alongside some of the senior obesity thought leaders and health care professionals from both public and private sector across India, in collaboration with Novo Nordisk India came together in Sep 2024, to deliberate on the cornerstones of obesity management in India. The day-long discussions yielded several critical recommendations for managing obesity as a public health priority and as a chronic disease in India. Since then, we’ve worked together to consolidate factual public health data & information, resulting in the development of a manuscript, which has now been published as a whitepaper. The article outlines the rapid rise in obesity prevalence, its clinical and socioeconomic implications, and emphasizes the importance of coordinated action across healthcare systems, policymakers, and community stakeholders to enable effective prevention and evidence-based management. As clinicians, we have a responsibility not only to treat obesity, but also to advocate for structured pathways of care that improve early detection, access to therapy, and long-term outcomes. Grateful for the continued collaboration and support from Novo Nordisk in advancing scientific dialogue and awareness around obesity as a chronic disease. Link to full text in the comment box #ClinicalObesity #ObesityInIndia #PublicHealth #NCDs #ChronicDisease #PreventiveHealthcare #HealthPolicy #EvidenceBasedMedicine #NovoNordisk #Diabetology #Endocrinology

“The Future of Diabetes Care in India Starts with CGM” Just published in “Diabetes therapy” Continuous Glucose Monitoring (CGM) has transformed diabetes care worldwide, yet its adoption in India remains limited due to challenges such as high costs, lack of awareness, infrastructure gaps, and sociocultural barriers. This narrative review highlights key unmet needs and emphasizes the importance of Real Time CGM use for proactive, data-driven, and preventive diabetes management. Addressing issues like affordability, accessibility, alarm fatigue, and stigma through India-specific solutions, education, and innovative, cost-effective technologies can significantly improve clinical outcomes and quality of life. Advancing CGM adoption is a crucial step toward equitable and future-ready diabetes care in India. #DiabetesCare #CGM #ContinuousGlucoseMonitoring #DiabetesInIndia #DigitalHealth #PreventiveCare #GlycemicControl #HealthInnovation #AffordableHealthcare #DiabetesAwareness link.springer.com/article/10.100…

@TharoorOffice @ShashiTharoor Wishing a speedy recovery 🙏🥰

After an X-ray this morning, Dr @ShashiTharoor’s injury has been confirmed as a fracture. He’s in good spirits and will continue with parliamentary work and other engagements as feasible (perhaps on a wheelchair). Thank you for all the good wishes! 💪🏼

Free Diabetes Treatment for 30 Children (Insulin & Libre CGM Sensors)- Kesavadev Trust Kanhangad, Kasaragod: In an event organised by P. Kesavadev Trust and Jothydev’s Diabetes Research Centre, free treatment assistance was provided to 30 children with diabetes. The initiative was inaugurated during a jointly organized diabetes education programme by Dr. Jothydev Kesavadev, who formally launched the project by handing over analogue insulin and Libre CGM sensors to Mr. Abdul Jaleel, representative of the Kerala Type 1 Diabetes Welfare Society, Kasaragod. As part of this programme, 30 economically underprivileged children with diabetes will receive six months of free treatment, including two types of analogue insulin injections (basal analogue and rapid-acting analogue). In addition, Libre Continuous Glucose Monitoring (CGM) systems were also provided free of cost to all 30 children. Statistics indicate that there are more than 4,500 children affected by Type 1 diabetes in Kerala. This condition is extremely challenging to manage. Since it is a relatively rare disease, it often does not receive adequate attention, which unfortunately leads to several associated complications. The recommended treatment for Type 1 diabetes involves the use of analogue insulin. Older insulin preparations fall under the category of human insulin. Although analogue insulin is slightly more expensive compared to human insulin, it significantly reduces the risk of dangerous low blood sugar episodes (hypoglycaemia). Kesavadev Trust is providing analogue insulin-not human insulin- free of cost for a period of six months to 30 children with diabetes. During the diabetes education programme, the unit head of Jothydev’s Diabetes Hospital Kasaragod, Dr. Shahana Yasmin and her team spoke on various topics. Dr. Jothydev Kesavadev answered queries from patients and their families. The programme was presided over by Mrs. Sunitha Jothydev, Director of Jothydev’s Diabetes Hospital. The event was coordinated by Mr. Hari Prasad, Public Relations Director of JDC. #FreeInsulin #CGMSupport #ContinuousGlucoseMonitoring #AnalogInsulin #DiabetesEducation #FreeDiabetesCare #DiabetesAwareness #Type1Diabetes #T1DChildren

A landmark event, the official launch of Yurpeak (tirzepatide), took place at the JPEF Mini CME, organized by Kesavadev Trust and Cipla, highlighting the latest advancements in Type 2 diabetes and weight management. Yurpeak, a dual GIP and GLP-1 receptor agonist, is being co-marketed in India by Cipla. Tirzepatide is a global blockbuster molecule, and with Cipla’s strong reach and execution capabilities, Yurpeak® is well positioned to be available across every nook and corner of India, effectively responding to the evolving needs of physicians and patients alike. The conference featured prominent faculty, including Dr. George Koshy, Dr. Mathew John, and Dr. Jothydev Kesavadev, who shared expert insights on redefining Type 2 diabetes management and the role of Yurpeak in weight management. The panel also included Dr. Arun Shankar, Dr. Praveen GK(Cardiologist), Dr. Noble Gracious(Nephrologist) and Dr. Rakesh S(Gastroenterologist) who engaged in discussions on practical approaches to improving patient outcomes. The event was organized by JPEF and Kesavadev Trust to promote high-quality medical education. #Yurpeak #Tirzepatide #JPEF #KKesavadevTrust #DiabetesCare #ObesityManagement #WeightManagement #GLP1 #GIP #Cipla #EliLilly #MedicalEducation #CME #Endocrinology #Diabetology #India #jothydevsprofessionaleducationforum @Cipla_Global

Scientific launch meeting of Afrezza,an inhaled insulin approved for use in diabetes mellitus, was held on January 21, 2026, at Residency Tower, Thiruvananthapuram. The programme was organised jointly by Jothydev’s Professional Education Forum (JPEF) and the P. Kesavadev Trust, with Cipla facilitating the introduction of Afrezza in India. The product is manufactured by MannKind Corporation, USA. The event was inaugurated by noted film actor Shri Maniyanpilla Raju. Senior physicians including Dr. Jothydev Kesavadev, Dr. Mathew John, Dr. Tittu Oomen, Dr. Thushanth Thomas, and Dr. Aneesh Ghosh served as faculty and participated in the scientific deliberations during the meeting. As part of continuing medical education, Dr. Jothydev Kesavadev presented available research data and practical guidance on the clinical use of inhaled insulin at a dedicated CME session. Afrezza is an ultra-rapid-acting inhaled mealtime insulin administered using a small inhaler device. It is intended for the control of post-meal glucose excursions in adults with diabetes. The features discussed during the meeting include: - Mealtime insulin delivered through oral inhalation - Rapid onset of action following inhalation - Availability in colour-coded cartridges of different dose strengths - Indicated for adults with Type 1 and Type 2 diabetes mellitus - Not approved for use in children #afreeza #InhaledInsulin #JPEF

@airindia The Vistara aircraft from Mumbai to Thiruvananthapuram was truly of international standards. 👍

Delighted to be part of the clinical trials team, especially meaningful as this is my first experience with an Indian original innovation 🇮🇳 Proud to be associated with Sun Pharma and India’s own original GLP-based molecule for diabetes and weight management. A significant milestone for Indian science and innovation. #Utreglutide #SunPharma #IndianInnovation #ClinicalTrials #DiabetesCare #ObesityManagement #GLP #MakeInIndia #MedicalResearch

Airindia tried to help us by upgrading our economy to premium economy. Realised that the originally paid nearby emergency exit seats are far far better for leg space! Had to fight with cabin crew to get back our close by exit row seats with leg space. Thanks Vysakh and the crew for helping us! Thanks Airindia for the outstanding service to a Maharaja Gold member. @airindia

Delighted to share our new review, published in the “International Journal of Diabetes and Technology” (IJDT)! ✨ We discuss the neuro-ophthalmic effects of GLP-1, with a focus on semaglutide and its potential protective role in conditions such as diabetic retinopathy, glaucoma, and idiopathic intracranial hypertension. By integrating metabolic, neuroprotective, and anti-inflammatory pathways, GLP-1RAs may represent a promising therapeutic bridge between diabetes care and vision preservation. Link to the free full text in the comment box #Semaglutide #GLP1 #DiabetesResearch #MetabolicHealth #Endocrinology #ObesityManagement #IJDT #MedicalScience #ClinicalResearch #NewPublication #VisionCare